We are live on ! Find out more
MIRM icon

Mirum Pharmaceuticals

214 hedge funds and large institutions have $2.82B invested in Mirum Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 76 increasing their positions, 80 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more capital invested

Capital invested by funds: $2.44B → $2.82B (+$375M)

1.35% more ownership

Funds ownership: 110.47%111.83% (+1.4%)

6% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 33

0% more funds holding

Funds holding: 214214 (0)

5% less repeat investments, than reductions

Existing positions increased: 76 | Existing positions reduced: 80

18% less funds holding in top 10

Funds holding in top 10: 119 (-2)

69% less call options, than puts

Call options by funds: $1.55M | Put options by funds: $5.06M

Holders
214
Holders Change
Holders Change %
0%
% of All Funds
2.82%
Holding in Top 10
9
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-18.18%
% of All Funds
0.12%
New
35
Increased
76
Reduced
80
Closed
33
Calls
$1.55M
Puts
$5.06M
Net Calls
-$3.51M
Net Calls Change
-$1.16M
Name Holding Trade Value Shares
Change
Change in
Stake
RIP
151
Reliant Investment Partners
North Carolina
$355K
Royal Bank of Canada
152
Royal Bank of Canada
Ontario, Canada
$337K -$15.7K -353 -5%
AIM
153
Aigen Investment Management
New York
$331K -$152K -3,425 -34%
GLA
154
Great Lakes Advisors
Illinois
$329K
AC
155
AXQ Capital
New Jersey
$290K +$254K +5,695 New
PWM
156
Palumbo Wealth Management
New York
$285K +$10.2K +228 +4%
CWM
157
CIBC World Markets
New York
$273K -$154K -3,456 -39%
HSBC Holdings
158
HSBC Holdings
United Kingdom
$272K -$16.2K -363 -6%
Envestnet Asset Management
159
Envestnet Asset Management
Illinois
$271K +$237K +5,329 New
CIM
160
Contravisory Investment Management
Massachusetts
$270K +$236K +5,307 New
TRCT
161
Tower Research Capital (TRC)
New York
$244K +$170K +3,810 +390%
Universal-Beteiligungs- und Servicegesellschaft
162
Universal-Beteiligungs- und Servicegesellschaft
Germany
$241K +$210K +4,726 New
EGM
163
Engineers Gate Manager
New York
$237K -$822K -18,470 -80%
AIP
164
Ameritas Investment Partners
Nebraska
$226K +$12.6K +284 +7%
AF
165
Avanza Fonder
Sweden
$211K +$56.8K +1,276 +44%
EFM
166
E Fund Management
China
$211K -$31.3K -704 -15%
SO
167
STRS Ohio
Ohio
$188K -$378K -8,500 -70%
SPIA
168
Steward Partners Investment Advisory
New York
$154K +$43.7K +981 +48%
NS
169
NBC Securities
Alabama
$146K +$128K +2,877 New
SG Americas Securities
170
SG Americas Securities
New York
$108K -$759K -17,056 -89%
Lazard Asset Management
171
Lazard Asset Management
New York
$99K -$1.78K -40 -2%
Mirae Asset Global Investments
172
Mirae Asset Global Investments
South Korea
$97.4K +$11K +248 +15%
US Bancorp
173
US Bancorp
Minnesota
$72.8K -$134 -3 -0.2%
AB
174
Amalgamated Bank
New York
$69K
KBC Group
175
KBC Group
Belgium
$65K -$31.1K -699 -36%

MIRM Hedge Fund Activity: Q2 2025 in Review

214 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Mirum Pharmaceuticals (MIRM) for Q2 2025, worth a combined $2.82B — up 15% from $2.44B a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new MIRM positions and 33 closed out — a net gain of 2 holders — while 76 added to existing stakes and 80 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $20.9M. The largest seller was Invesco, cutting an estimated $11.1M.

  • 214 institutional investors held Mirum Pharmaceuticals (MIRM) as of Q2 2025, unchanged from Q1 2025.
  • Funds reported $2.82B of Mirum Pharmaceuticals stock for Q2 2025, up 15% quarter-over-quarter.
  • 35 funds opened new Mirum Pharmaceuticals positions in Q2 2025 and 33 closed out, a net change of +2 holders.
  • The largest Mirum Pharmaceuticals buyer in Q2 2025 was Janus Henderson Group, an estimated $20.9M added.
  • The largest Mirum Pharmaceuticals seller in Q2 2025 was Invesco, an estimated $11.1M sold.

Based on aggregated 13F filings for Q2 2025.